pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 11·1 min read
save

Genentech shuts infectious disease research unit and lays off senior scientists in latest R&D cuts

Jun 11, 2026·read at Endpoints ↗LayoffsNegative

Genentech announced another round of layoffs affecting its early research and development group.

The cuts included the closure of its infectious disease research unit and the departure of several senior scientists, such as Vishva Dixit.

The restructuring reflects a broader effort to streamline R&D operations, though the specific reasons were not detailed in the report.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Exclusive: Genentech closes infectious disease unit in wave of research layoffs”

read at Endpoints ↗
87 words · retrieved Jun 11
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
GENENTECH3ROCHE2
topics
Infectious Disease2

related stories

  • 14h agoTScan axes 75% of workforce, prioritizes solid tumor programBioSpace
  • Dec 23Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount dropFierce Biotech
  • Dec 22Fierce Biotech Fundraising Tracker '26: Superluminal snags $60M; AusperBio adds $120MFierce Biotech
  • 3d agoRoche finds another oncology gem in Asia with $1.5B B cell disease partnershipBioSpace
  • 3d agoArsenalBio sheds most of staff in pivot to in vivo CAR-TFierce Biotech